Advances and Aspirations in T-AML and AML-MRC - From Bench to Bedside
06 Nov 2024
About the event
An event looking at the management of patients with T-AML and AML-MRC and how Vyxeos Liposomal has been developed for the treatment of this population of patients. The importance of HSCT as a treatment goal in this group and how the gut microbiome is linked to transplant outcomes. There will be ample opportunity to ask questions of the panel with a 15 minute Q&A at the end of the presentations.
Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
